p53 and MDM2 in the development and progression of bladder cancer.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  European Urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000480813PMID 9412812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines

  2004cited by this paper
• P53 accumulation in precursor lesions and early stages of bladder cancer

  2004cited by this paper
• Expression of mdm-2 and p53 protein in transitional cell carcinoma

  2004cited by this paper
• Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer

  1996cited by this paper
• Overexpression of MDM‐2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines

  1995cited by this paper
• Altered patterns of MDM2 and TP53 expression in human bladder cancer.

  1994cited by this paper
• Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.

  1994cited by this paper
• Physical and functional interaction between wild-type p53 and mdm2 proteins

  1994cited by this paper
• mdm2 expression is induced by wild type p53 activity.

  1993cited by this paper
• Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53.

  1993cited by this paper
• The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth

  1993cited by this paper
• Role of chromosome 9 in human bladder cancer.

  1993cited by this paper
• p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

  1993cited by this paper
• WAF1, a potential mediator of p53 tumor suppression.

  1993cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

  1993cited by this paper
• Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.

  1993cited by this paper
• Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

  1993cited by this paper
• Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype.

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Frequent association of p53 gene mutation in invasive bladder cancer.

  1992cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper
• Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.

  1992cited by this paper
• Urothelial dysplasia.

  1982cited by this paper

• Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression

  2025cites this paper
• Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity

  2025cites this paper
• Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression

  2024cites this paper
• Cucurbitacin B Inhibits the Proliferation of WPMY-1 Cells and HPRF Cells via the p53/MDM2 Axis

  2024cites this paper
• The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy

  2023cites this paper
• circNUDT21 promotes bladder cancer progression by modulating the miR-16-1-3p/MDM2/p53 axis

  2021cites this paper
• Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma.

  2021cites this paper
• Aspects of Development and Progression of Bladder Cancer 2

  2019cites this paper
• MicroRNA-379-5p plays a tumor-suppressive role in human bladder cancer growth and metastasis by directly targeting MDM2.

  2017cites this paper
• Tp53 and its potential therapeutic role as a target in bladder cancer

  2017cites this paper
• Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4th Edition Guidelines as a Molecular Insight towards Personalized Medicine

  2017cites this paper
• Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example

  2016cites this paper
• Target genes of recurrent chromosomal amplification and deletion in urothelial carcinoma.

  2014cites this paper
• Biomarkers in bladder cancer: translational and clinical implications.

  2014influential citation
• Mdm2 SNP309 G-Variant Is Associated with Invasive Growth of Human Urinary Bladder Cancer

  2013cites this paper
• Mdm 2 SNP 309 G-Variant Is Associated with Invasive Growth of Human Urinary Bladder Cancer

  2013cites this paper
• Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population

  2012cites this paper
• Tissue‐based Biomarkers

  2012cites this paper
• P 53 / MDM 2 CO-EXPRESSION CORRELATES WITH THE TUMOUR DIFFERENTIATION IN ORAL SQUAMOUS CELL CARCINOMA – A RETROSPECTIVE STUDY

  2012cites this paper
• Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

  2012cites this paper
• P53/MDM2 co-expression correlates with the tumour differentiation in oral squamous cell carcinoma - a retrospective study and a systematic review

  2011cites this paper
• The Emphasis of Tumor Suppressor Genes and Oncogenes in Diagnosis and Prognosis of Anaplastic Brain Tumors

  2011cites this paper
• p53 immunohistochemistry in bladder cancer--a new approach to an old question.

  2010cites this paper
• Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids.

  2010cites this paper
• Molecular pathogenesis of urothelial carcinoma: the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer.

  2009cites this paper
• A Novel Functional Polymorphism C1797G in the MDM2 Promoter Is Associated with Risk of Bladder Cancer in a Chinese Population

  2008cites this paper
• Proteomics and genomics of urinary bladder cancer

  2008cites this paper
• Functional Polymorphism C 1797 G in the MDM 2 Promoter Is Associated with Risk of Bladder Cancer in a Chinese Population

  2008cites this paper
• A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer

  2007cites this paper
• Epidemiology of urinary bladder cancer: from tumor development to patient’s death

  2007cites this paper
• MDM2/p53 protein expression in the development of colorectal adenocarcinoma

  2007cites this paper
• Molecular biology of bladder cancer

  2007cites this paper
• Targeted therapies in the management of metastatic bladder cancer

  2007cites this paper
• Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment.

  2006cites this paper
• Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

  2006cites this paper
• Molecular genetics of bladder cancer: targets for diagnosis and therapy.

  2006cites this paper
• p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.

  2006cites this paper
• Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.

  2006cites this paper
• MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

  2005cites this paper
• Molekulare Prognosemarker des Harnblasenkarzinoms

  2005cites this paper
• P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

  2005cites this paper
• Alteration of the MDM2-p73-P14ARF pathway related to tumour progression during urinary bladder carcinogenesis.

  2004cites this paper
• Respuesta a la carta al Director titulada: Referencia al artículo: Análisis multivariado de recidiva y progresión en el carcinoma de células transicionales de vejiga en estadio T1. Valor pronóstico de p53 y ki67.

  2003cites this paper
• Perspektiven der molekularen Diagnostik dargestellt am Beispiel des Harnblasenkarzinoms

  2003cites this paper
• Molecular pathology of non-invasive urothelial carcinomas (part I)

  2003cites this paper
• [Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage].

  2003cites this paper
• Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder.

  2003cites this paper
• Molecular pathogenesis of urothelial bladder cancer.

  2003cites this paper
• [Reply to the letter: "In reference to the article: Multivariate analysis of recurrence and progression of stage T1 transitional cell carcinoma of the bladder. Prognostic value of p53 and kI67].

  2003cites this paper
• [Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67].

  2003cites this paper
• [Perspectives for molecular diagnostics exemplified by urothelial bladder carcinoma].

  2003cites this paper
• Análisis multivariado de recidiva y progresión en el carcinoma de células transicionales de vejiga en estadio T1: Valor pronóstico de p53 y ki67

  2003cites this paper
• Estudio comparativo de la expresión de p53, Ki67, bcl-2 y CK20 en el carcinoma transicional superficial de vejiga: correlación con la recurrencia, grado histológico y estadio clínico

  2003cites this paper
• Multivariate analysis of recurrence and progression in stage T1 transitional cell bladder carcinoma: Prognostic value of p53 and ki67

  2003cites this paper
• Prognostic value of p53 and MDM2 Expression in Bilharziasis-Associated Squamous Cell Carcinoma of the Urinary Bladder

  2003cites this paper
• The prognostic value of MDM2 overexpression in superficial urothelial bladder carcinoma

  2002cites this paper
• Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer

  2002cites this paper
• Quality assurance in interstitial iridium-192 implants for breast cancer

  2002cites this paper
• Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy.

  2002cites this paper
• Prognostic value of p53 overexpression in bladder tumors treated with Bacillus Calmette-Guerin

  2002cites this paper
• Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma

  2002cites this paper
• Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.

  2002cites this paper
• Biology and Molecular Aspects of Development and Progression of Bladder Cancer

  2001cites this paper
• Nutzung tumorspezifischer Veränderungen für die selektive Reexpression des Tumorsuppressorgens p53 in Harnblasenkarzinomen

  2001cites this paper
• [Usefulness of p53 in the clinical management of bladder tumors].

  2001cites this paper
• p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?

  2000cites this paper
• p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer

  2000cites this paper
• Tumorigenic pathways in low‐stage bladder cancer based on p53, MDM2 and p21 phenotypes

  2000cites this paper
• Mutation of cell cycle regulators and their impact on superficial bladder cancer.

  2000cites this paper
• Biología molecular en el cáncer vesical

  2000cites this paper
• p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go?

  2000cites this paper
• Allelic deletions of cell growth regulators during progression of bladder cancer.

  2000influential citation
• Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.

  2000cites this paper
• MDM2 Overexpression with Alteration of the p53 Protein and Gene Status in Oral Carcinogenesis

  2000cites this paper
• Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter

  2000cites this paper
• [Molecular biology in bladder cancer].

  2000cites this paper
• P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers.

  2000cites this paper
• Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators?

  1999cites this paper
• Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.

  1999cites this paper
• Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.

  1999cites this paper
• Indikationen zur Zystektomie und Wahl der Harnableitung — Welche Entscheidungsparameter stehen zur Verfügung?

  1998cites this paper
• p53 and p53-regulated genes in bladder cancer.

  1998cites this paper
• MicroRNA-379-5 p plays a tumor-suppressive role in human bladder cancer growth and metastasis by directly targeting MDM 2

  year unknowncites this paper